Form 4: Vera Therapeutics Director Granted Stock Options

Vera Therapeutics Director James R Meyers was granted 25,000 stock options with an exercise price of $29.43, vesting over three years.

Summary

• James R Meyers, a Director of Vera Therapeutics, Inc. (VERA), was granted 25,000 stock options.
• The transaction date for the option grant was November 25, 2025.
• Each stock option has an exercise price of $29.43.
• The options will vest monthly over a three-year period, contingent on Mr. Meyers' continuous service.
• Full vesting of the options will occur upon a change in control, provided continuous service through that date.
• The expiration date for these stock options is November 24, 2035.
• Following this transaction, Mr. Meyers beneficially owns 25,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The grant of stock options to a director is generally a neutral to slightly positive event, as it aligns the director's interests with shareholders and is a standard form of compensation. It does not indicate any immediate operational or financial performance changes.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• The vesting schedule encourages the director's continued service to the company over a three-year period.

Future Outlook

The stock options are subject to a three-year monthly vesting schedule, contingent on the director's continuous service. Full vesting will accelerate upon a change in control, also subject to continuous service.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages to attract and retain talent and align interests with shareholders.

Comparison to Industry Standards

• Granting stock options to directors is a standard compensation practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The three-year vesting period is a common structure designed to promote long-term commitment and performance from board members.
• The inclusion of a change-in-control acceleration clause is also a typical feature in such agreements, providing protection and incentive in M&A scenarios.

Stakeholder Impact

• Shareholders: The option grant aligns the director's incentives with shareholder value creation, potentially leading to more focused long-term decision-making.

Next Steps

• The stock options will continue to vest monthly over the next three years, subject to the director's continuous service.

Key Dates

Keywords

Vera Therapeutics, VERA, stock options, insider transaction, Form 4, director compensation, equity compensation